Clinical Breast Cancer
@CBCjournal
Followers
320
Following
174
Media
17
Statuses
126
Official account of CBC, a journal publishing 8 issues/year on various aspects of clinical & translational breast cancer research. IF 3.225 | RTs ≠ endorsement.
Joined March 2022
Progesterone receptor (PR) expression in #BreastCancer is more than a biomarker. 🔹 Analysis of 2,223 pts (IPO-Porto) 🔹 PR status linked to BMI, histology, grade, stage, ER & HER2 🔹 PR– tumors associated with advanced stage & worse OS #bcsm
https://t.co/pw3eavkJ7R
0
0
0
Is breast-conserving therapy (BCT) safe for multifocal/multicentric breast cancer (MF/MCBC)? 🔹Meta-analysis (28,589 pts) 🔹 MF/MCBC had higher LR vs unifocal disease 🔹 LR rates comparable btw BCT & mastectomy 🔹 DFS & OS outcomes favorable #bcsm
https://t.co/cSvnBpSbI2
clinical-breast-cancer.com
The appropriateness of BCT for MF/MCBC is debated, with concerns about higher recurrence rates. This study aims to provide an updated systematic review and meta-analysis of LR and survival outcomes...
0
0
0
Solution 🌳of Sustainability for Breast Cancer Care 👇 Grateful to ✍️ co- authors for their insights
Climate change is the greatest threat to human health—and it directly impacts BC care. This review maps intersections between breast cancer care & planetary health and proposes a solution tree for sustainable, low-carbon practice. #bcsm
@Seamusoreilly18
https://t.co/LxOrKcsddC
0
5
20
Climate change is the greatest threat to human health—and it directly impacts BC care. This review maps intersections between breast cancer care & planetary health and proposes a solution tree for sustainable, low-carbon practice. #bcsm
@Seamusoreilly18
https://t.co/LxOrKcsddC
0
0
3
Black women face higher breast cancer mortality despite similar incidence to White women. 🧬 Universal genetic counseling/testing could aid earlier risk identification ⚡ Higher TNBC rates & earlier onset already meet NCCN criteria #bcsm @sofiamerajver
https://t.co/jwiEQ6Ll95
clinical-breast-cancer.com
Black women experience disproportionate breast cancer-related mortality, with similar overall incidence to White women. Approaches to address these racial health disparities should be multifaceted....
0
0
0
💡 In HER2+ breast cancer patients who achieve pCR after neoadjuvant chemo + trastuzumab/pertuzumab (TP), adjuvant therapy choice may not impact outcomes. 👉 3-yr RFS: 94.2% (TP) vs 95.6% (T) 👉 No differences in brain mets or survival #bcsm #CBCjournal
https://t.co/OANpokwcDV
clinical-breast-cancer.com
MicroabstractIn this retrospective study, we compared survival outcomes according to the type of adjuvant anti-HER2 therapy in patients with pCR after chemotherapy with trastuzumab and pertuzumab....
0
0
2
A new article was published in Clinical Breast Cancer by the cancer center’s Tarah Ballinger, MD, and colleagues. Learn more: https://t.co/sLF0rwr716.
#ResearchCuresCancer #NCIcomprehensive @CBCjournal
0
1
2
New meta-analysis: Tranexamic acid (TXA) significantly reduces postoperative hematoma after breast surgery. 🔹 Both topical & IV TXA cut hematoma risk 🔹 Less drain output & earlier drain removal 🔹 No increase in infection or thromboembolic events #bcsm
https://t.co/WmAD6wXIAf
0
1
0
PreciseDx Breast is a digital risk assessment test that predicts early BC recurrence within 6-years of diagnosis. Read more👇 #bcsm @IcahnMountSinai
https://t.co/2fYW9kgAbu
0
0
0
Radiation omission in pts w/ early BC is a dynamically changing paradigm. Individualizing treatment is paramount and understanding an individual pt's goals of treatments and values is key. Read more 👇 #bcsm
@RoswellPark @si_fkf @MFarrugiaXRT @CShahMD
https://t.co/ZFPoOYjua4
clinical-breast-cancer.com
Micro abstractWe discuss the most recent data evaluating omission of RT for early-stage breast cancer following BCS, review ongoing studies, and highlight alternative approaches for deescalation of...
0
2
5
A study evaluating forequarter amputation (FA) in BC (locally advanced/recurrent tumor, Stewart & Treves syndrome, radiation-induced sarcoma) showed that FA has few complications & attenuates symptoms in pts tx with both curative & palliative intent. https://t.co/iDehbg3ljC
0
0
2
🔔Hot off the press! Optimizing Postneoadjuvant Treatment of Residual #BreastCancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy 🔓Free access until 03/21: https://t.co/ZcaIu2PkED ✍️@CBCjournal @darioT_ @JinQingchun @hoperugo
@YAbdouMD
0
14
29
A Clinical Review on Antibody-Drug Conjugates in TNBC, summarizing Current Data and Future Developments. @kilicmerwe @WinshipAtEmory
pubmed.ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for...
0
1
2
Just published in the February 2025 issue of Clinical Breast Cancer @CBCjournal Congratulations to Professor Yihong Wang and colleagues @BrownMedicine @BrownUCancer @BrownPathology In our study of 224 node-positive breast cancer patients treated with neoadjuvant
0
5
13
A Clinical Review of the Role of Immunotherapy in TNBC, with an Overview of Data from Seminal Trials for both Early and Advanced TNBC. #bcsm
@RitaNandaMD @UChicagoMed
https://t.co/rWf16YatFV
0
0
0
NH Black women have ⬆️ risk of TNBC yet, they are less likely to undergo genetic counseling / testing and less likely to receive guideline-directed screening and risk-reduction compared to NH White women. #bcsm #disparities
@dsmithgraz @WinshipAtEmory
https://t.co/9nnkWoeyTI
pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately affects younger females, non-Hispanic Black women, Hispanic women, and women with the BRCA1 gene...
0
1
1
Effect of BC Receptor Subtypes and CSF Cytology Status on Survival of BC Patients w/ Leptomeningeal Disease. #bcsm @CBCjournal
@DhakalAjay @CareyAnders1 @oreganruth @WilmotCancer @DukeCancer
https://t.co/N56PRpLEjb
0
0
0
A Clinical Review of Subcutaneous (SC) Trastuzumab and Pertuzumab in treating early-stage and metastatic HER2+ BC, highlighting benefits of SC vs IV formulations. Check out more 👇 @atanmdlci @levinecancer
@AtriumHealth
#bcsm #CBCjournal
https://t.co/nWm5n09RTV
pubmed.ncbi.nlm.nih.gov
Therapy directed against human epidermal growth factor receptor type 2 (HER2) is the standard of care for patients with early-stage and metastatic HER2-positive breast cancer. Treating patients with...
0
0
1
A new study in @CBCjournal shows mobile #mammography helps increase breast cancer screening in underserved areas, especially among Indigenous, rural, & low-income women. It complements facility-based screenings and improves early detection. #HealthEquity
https://t.co/pPWuInhKcq
neimanhpi.org
A recent study by the Harvey L. Neiman Health Policy Institute demonstrates that mobile mammography is generally used by women otherwise unlikely to be screened, and thus is complementary to facili…
0
3
4
Check out on @CBCjournal our review of comparative evidence from clinical studies with metronomic versus standard-dose regimens. @darioT_ @BattaiottoElena
https://t.co/YiOLccYmil
0
2
6